Comparison 9. Triphasic NET 500‐750‐1000 μg and EE 35 μg versus monophasic LNG 100 μg and EE 20 μg.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Pregnancy per woman within 4 cycles	2	729	Odds Ratio (M‐H, Random, 95% CI)	1.97 [0.36, 10.83]
2 Proportion of cycles with spotting within 3 cycles	1	756	Odds Ratio (M‐H, Random, 95% CI)	1.08 [0.70, 1.67]
3 Proportion of cycles with breakthrough bleeding within 3 cycles	1	756	Odds Ratio (M‐H, Random, 95% CI)	0.95 [0.50, 1.78]
4 Proportion of cycles with spotting and breakthrough bleeding within 3 cycles	1	756	Odds Ratio (M‐H, Random, 95% CI)	1.10 [0.77, 1.57]
5 Proportion of cycles with intermenstrual bleeding within 3 cycles	2	1367	Odds Ratio (M‐H, Random, 95% CI)	1.22 [0.96, 1.54]
6 Proportion of women with spotting at cycle 3	1	232	Odds Ratio (M‐H, Random, 95% CI)	2.03 [0.74, 5.54]
7 Proportion of women with breakthrough bleeding at cycle 3	1	232	Odds Ratio (M‐H, Random, 95% CI)	1.52 [0.53, 4.33]
8 Proportion of women with spotting and breakthrough bleeding at cycle 3	1	232	Odds Ratio (M‐H, Random, 95% CI)	0.73 [0.39, 1.38]
9 Proportion of women with intermenstrual bleeding at cycle 3	2	420	Odds Ratio (M‐H, Random, 95% CI)	1.18 [0.79, 1.75]
10 Proportion of cycles with amenorrhea within 3 cycles	2	1367	Odds Ratio (M‐H, Random, 95% CI)	0.87 [0.51, 1.48]
11 Proportion of women with amenorrhea at cycle 3	2	330	Odds Ratio (M‐H, Random, 95% CI)	0.38 [0.07, 1.92]
12 Total discontinuation within 4 cycles	2	729	Odds Ratio (M‐H, Random, 95% CI)	0.83 [0.62, 1.11]
13 Discontinuation due to medical reasons within 4 cycles	2	729	Odds Ratio (M‐H, Random, 95% CI)	0.68 [0.31, 1.47]